LONDON - Graft Polymer (LON:GPL), a biotechnology company specializing in co-developing therapeutics for mental health disorders, announced today that its shareholders have approved a resolution to change the company’s name to Solvonis Therapeutics plc. The decision came during a general meeting held earlier today, where the resolution passed on a show of hands.
The proxy votes tallied prior to the meeting revealed strong support for the initiative, with 99.53% of votes cast in favor and 0.47% against the change. No votes were withheld in the process. Following shareholder approval, the company will proceed with the necessary formalities at Companies House to make the name change official. An announcement will be made once the change has been formally enacted.
The change of name will also result in an update to the company’s TIDM, transitioning from "GPL" to "SVNS." However, the ISIN and SEDOL numbers, GB00BMD1Z199 and BMD1Z19 respectively, associated with the company’s ordinary shares will remain the same. Current shareholders of Graft Polymer will not be affected by this change, and existing share certificates will continue to be valid and should be retained.
This development is part of the company’s ongoing efforts to align its corporate identity with its strategic focus on mental health therapeutics. The information is based on a press release statement from Graft Polymer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.